Human Renal Cell Carcinoma Antigen-specific CTLs: Antigen-driven Selection and Long-term Persistence in Vivo
Overview
Authors
Affiliations
Renal cell carcinomas (RCCs) are thought to be immunogenic, because cytokine-induced and even spontaneous tumor regression has been observed in a significant number of patients. However, little is known about the nature of immune responses that might lead to tumor regression. We studied naturally arising human T-cell responses against RCC by combining molecular analyses of T-cell receptor (TCR) usage in primary tumors in situ with functional analyses of tumor-infiltrating lymphocytes (TILs) in vitro. TILs of patient 26 that were cultured in vitro showed a human leukocyte antigen (HLA-A*0201)-restricted cytotoxic activity specific for autologous tumor cells. These tumor-derived lymphocytes were dominated by a family of T cells expressing V alpha20- and V beta22-positive TCRs. Their specificity-conferring third complementarity-determining regions were highly homologous with respect to the loop length and selection of particular amino acids in both TCR chains. These characteristics are similar to those reported for antigen-selected murine T cells recognizing immunodominant epitopes of non-self proteins. To evaluate the biological significance of these CTLs in vivo, we analyzed the corresponding TCR transcripts in the cryopreserved tumor material of patient 26 and in a second HLA-A*0201-positive RCC patient whose tumor cells were also lysed by TIL-26. The in situ TIL populations of both patients used related families of highly homologous TCRs, supporting the contention that immunodominant responses directed against a shared tumor-associated antigen occurred in both individuals in vivo. Furthermore, in the absence of overt metastatic disease, the tumor antigen-specific CTLs of patient 26 were shown to persist in the periphery 4 years after removal of the primary tumor. These results demonstrate that antigen-driven T-cell responses specific for spontaneously arising carcinomas developed in these patients and showed long-term persistence, even in the absence of immunotherapy.
Barnkob M, Michaels Y, Andre V, Macklin P, Gileadi U, Valvo S Nat Commun. 2024; 15(1):3173.
PMID: 38609390 PMC: 11017241. DOI: 10.1038/s41467-024-47424-z.
Brech D, Herbstritt A, Diederich S, Straub T, Kokolakis E, Irmler M Cells. 2022; 11(20).
PMID: 36291154 PMC: 9600747. DOI: 10.3390/cells11203289.
Guo L, Bi X, Li Y, Wen L, Zhang W, Jiang W J Pathol. 2020; 251(1):26-37.
PMID: 32073142 PMC: 7317472. DOI: 10.1002/path.5396.
Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
Brodaczewska K, Szczylik C, Kieda C Contemp Oncol (Pozn). 2018; 22(1A):14-22.
PMID: 29628789 PMC: 5885083. DOI: 10.5114/wo.2018.73878.
Nukui A, Masuda A, Abe H, Arai K, Yoshida K, Kamai T BMC Cancer. 2017; 17(1):372.
PMID: 28545581 PMC: 5445282. DOI: 10.1186/s12885-017-3369-3.